4-((3R,3'S)-3-(3,5-dichlorophenyl)-2'-oxo-1,3'-bipyrrolidin-1'-yl)-N-(thiazol-2-yl)benzenesulfonamide

ID: ALA2324353

Chembl Id: CHEMBL2324353

PubChem CID: 44603427

Max Phase: Preclinical

Molecular Formula: C23H22Cl2N4O3S2

Molecular Weight: 537.49

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1[C@@H](N2CC[C@H](c3cc(Cl)cc(Cl)c3)C2)CCN1c1ccc(S(=O)(=O)Nc2nccs2)cc1

Standard InChI:  InChI=1S/C23H22Cl2N4O3S2/c24-17-11-16(12-18(25)13-17)15-5-8-28(14-15)21-6-9-29(22(21)30)19-1-3-20(4-2-19)34(31,32)27-23-26-7-10-33-23/h1-4,7,10-13,15,21H,5-6,8-9,14H2,(H,26,27)/t15-,21-/m0/s1

Standard InChI Key:  YGHCKDOMNUKAHH-BTYIYWSLSA-N

Associated Targets(Human)

SCN3A Tclin Sodium channel protein type III alpha subunit (275 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Scn3a Sodium channel protein type III alpha subunit (24 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Scn1a Sodium channel protein type I alpha subunit (7 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 537.49Molecular Weight (Monoisotopic): 536.0510AlogP: 4.85#Rotatable Bonds: 6
Polar Surface Area: 82.61Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 6.91CX Basic pKa: 6.22CX LogP: 3.57CX LogD: 3.42
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.49Np Likeness Score: -1.63

References

1. Bagal SK, Brown AD, Cox PJ, Omoto K, Owen RM, Pryde DC, Sidders B, Skerratt SE, Stevens EB, Storer RI, Swain NA..  (2013)  Ion channels as therapeutic targets: a drug discovery perspective.,  56  (3): [PMID:23121096] [10.1021/jm3011433]
2. Pryde DC, Swain NA, Stupple PA, West CW, Marron B, Markworth CJ, Printzenhoff D, Lin Z, Cox PJ, Suzuki R, McMurray S, Waldron GJ, Payne CE, Warmus JS, Chapman ML..  (2017)  The discovery of a potent Nav1.3 inhibitor with good oral pharmacokinetics.,  (6): [PMID:30108836] [10.1039/C7MD00131B]

Source